CELG,Morphosys CEO says MOR202 drug candidate still promising - newspaper FRANKFURT, April 5 Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper. 
